CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentation
Abstract Macrophage-based cancer cellular therapy has gained substantial interest. However, the capability of engineered macrophages to target cancer heterogeneity and modulate adaptive immunity remains unclear. Here, exploiting the myeloid antibody-dependent cellular phagocytosis biology and phagoc...
Saved in:
| Main Authors: | Siqi Chen, Yingyu Wang, Jessica Dang, Nuozi Song, Xiaoxin Chen, Jinhui Wang, Guo N. Huang, Christine E. Brown, Jianhua Yu, Irving L. Weissman, Steven T. Rosen, Mingye Feng |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-04-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-025-59326-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy
by: Bolan Yu, et al.
Published: (2022-02-01) -
Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker
by: Tomás A. Martins, et al.
Published: (2024-11-01) -
CD47 antibody-armed oncolytic adenovirus promotes chimeric antigen receptor macrophage phagocytosis and antitumor immunity
by: Zhongbing Qi, et al.
Published: (2025-08-01) -
Why people use their cars while the built environment imposes cycling
by: Veronique Van Acker, et al.
Published: (2013-04-01) -
Built environment and car driving distance in a small city context
by: Fitwi Wolday
Published: (2018-10-01)